التفاصيل البيبلوغرافية
| العنوان: |
Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials |
| المؤلفون: |
Dai, Haibing, Zhu, Yonglin, Chen, Zuyi, Yan, Renqing, Liu, Jinsong, He, Ziyun, Zhang, Lin, Zhang, Feng, Yan, Shengkai |
| المصدر: |
Endokrynologia Polska; Vol 74, No 3 (2023); 234-242 |
| بيانات النشر: |
Via Medica |
| سنة النشر: |
2023 |
| المجموعة: |
Via Medica Journals |
| مصطلحات موضوعية: |
familial hypercholesterolaemia, lipoprotein (a), atherosclerotic cardiovascular disease, PCSK9 inhibitors, meta-analysis, randomized controlled trials |
| الوصف: |
Introduction: Familial hypercholesterolaemia (FH) is a common hereditary genetic disorder, characterized by elevated circulating low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] concentrations, leading to atherosclerotic cardiovascular disease (ASCVD). Two types of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors — alirocumab and evolocumab — are efficient drugs in the treatment of FH, which can effectively reduce Lp(a) levels. Material and methods: Embase, MEDLINE, and PubMed up to November 2022 were searched for randomized clinical trials (RCTs) evaluating the effect of alirocumab/evolocumab and placebo treatment on plasma Lp(a) levels in FH. Statistics were analysed by Review Manager (RevMan 5.3) and Stata 15.1. Results: Eleven RCTs involved a total of 2408 participants. Alirocumab/evolocumab showed a significant efficacy in reducing Lp(a) [weighted mean difference (WMD): –20.10%, 95% confidence interval (CI): –25.59% to –14.61%] compared with placebo. In the drug type subgroup analyses, although the efficacy of evolocumab was slightly low (WMD: –19.98%, 95% CI: –25.23% to –14.73%), there was no difference with alirocumab (WMD: –20.54%, 95% CI: –30.07% to –11.02%). In the treatment duration subgroup analyses, the efficacy of the 12-week duration group (WMD: –17.61%, 95% CI: –23.84% to –11.38%) was lower than in the group of ≥ 24 weeks’ duration (WMD: –22.81%, 95% CI: –31.56% to –14.07%). In the participants’ characteristics subgroup analyses, the results showed that no differential effect of alirocumab/evolocumab therapy on plasma Lp(a) concentrations was observed (heterozygous FH [HeFH] WMD: –20.07%, 95% CI: –26.07% to –14.08%; homozygous FH [HoFH] WMD: –20.04%, 95% CI: –36.31% to –3.77%). Evaluation of all-cause adverse events (AEs) between alirocumab/evolocumab groups and placebo groups [relative risk (RR): 1.05, 95% CI: 0.98–1.12] implied no obvious difference between the 2 groups. Conclusions: Anti-PCSK9 drugs (alirocumab and evolocumab) may be effective as therapy ... |
| نوع الوثيقة: |
other/unknown material |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
https://journals.viamedica.pl/endokrynologia_polska/article/view/EP.a2023.0036Test |
| DOI: |
10.5603/EP.a2023.0036 |
| الإتاحة: |
https://doi.org/10.5603/EP.a2023.0036Test
https://journals.viamedica.pl/endokrynologia_polska/article/view/EP.a2023.0036Test |
| حقوق: |
Completion of the online submission form electronically is tantamount to automatically and free-of-charge transferring of the copyright for publishing and distribution of the submitted material (in all known now and developed in the future forms and fields of exploitation) to the copyright holder, i.e. Polish Society of Endocrinology, under condition that those materials are accepted for publication. The authors agree not to publish any data or figures presented in their work anywhere and in any language without the prior written consent. ; Przesyłając manuskrypt wraz z ilustracjami i tabelami, Autorzy automatycznie i nieodpłatnie przenoszą na Polskie Towarzystwo Endokrynologiczne i "Endokrynologię Polską" wszelkie prawa autorskie do wydawania oraz rozpowszechniania nadesłanych materiałów we wszystkich znanych formach i na wszystkich znanych polach eksploatacji, bez ograniczeń terytorialnych językowych, pod warunkiem że materiały te zostaną zaakceptowane do publikacji. Publikacja w całości ani w żadna jej część nie może być powielana ani upowszechniana w jakikolwiek mechaniczny lub elektroniczny sposób bez pisemnej zgody Redaktora Naczelnego. |
| رقم الانضمام: |
edsbas.D1453D8C |
| قاعدة البيانات: |
BASE |
